Oxytocin vs PT-141
Head-to-head comparison of Oxytocin (Neurohypophysial Hormone Peptide) and PT-141 (Bremelanotide (Melanocortin Receptor Agonist)) — benefits, dosing, side effects, research data, and where to buy.
| Property | Oxytocin | PT-141 |
|---|---|---|
| Category | Performance | Performance |
| Full Name | Neurohypophysial Hormone Peptide | Bremelanotide (Melanocortin Receptor Agonist) |
| Molecular Weight | 1,007.19 Da | 1,025.2 Da |
| Half-Life | ~3-5 minutes (plasma) | ~2.7 hours |
| Amino Acids | 9 | 7 |
| Typical Dose | 20-40 IU intranasal | 1.75 mg |
| Route | Intranasal / IV / IM | SC |
| Purity | — | — |
| Studies Count | 1850 | 178 |
| Research Status | FDA Approved (Pitocin) | FDA Approved |
Oxytocin Benefits
- ✓Enhances social bonding and trust
- ✓Reduces social anxiety
- ✓Emotional regulation
- ✓Potential autism spectrum benefits
- ✓Stress and anxiety reduction
PT-141 Benefits
- ✓Enhances sexual desire and arousal
- ✓Works through CNS (not vascular)
- ✓FDA-approved for HSDD
- ✓Effective for both men and women
- ✓Does not require sexual stimulation to work
Oxytocin Dosing
Intranasal: 20-40 IU per dose, 1-2 times daily|Social Anxiety: 24 IU intranasal 45 min before social situations|Research: 8-40 IU per administration|Clinical: Per physician protocol
PT-141 Dosing
Standard: 1.75 mg SC, 45 min before activity|Max frequency: Once every 24 hours|Max: 8 doses per month|Men (off-label): 1-2 mg SC as needed
Oxytocin Side Effects
- ⚠Common (Intranasal): Nasal irritation, headache, drowsiness
- ⚠Moderate: Uterine contractions (caution in pregnancy)
- ⚠Rare: Water retention at high doses
- ⚠Contraindications: Pregnancy (non-medical), cardiovascular disease
PT-141 Side Effects
- ⚠Common: Nausea (40%), flushing, headache, injection site reactions
- ⚠Moderate: Elevated blood pressure (transient), fatigue
- ⚠Serious: Focal hyperpigmentation with repeated use
- ⚠Contraindications: Uncontrolled hypertension, cardiovascular disease
Research Overview
Oxytocin
Oxytocin has extensive research and is one of the most studied hormonal peptides. FDA-approved for obstetric use. Intranasal formulations being studied for autism spectrum disorder, social anxiety, PTSD, and depression. Complex dose-response relationships being elucidated.
PT-141
PT-141 has robust clinical evidence including multiple Phase III trials. FDA-approved in 2019. Unique mechanism of action through melanocortin-4 receptors in the brain. Well-characterized safety and efficacy profile.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.